Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

NCT02183636 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Linagliptin/pioglitazone, FDC formulation C5
DRUG: Linagliptin/pioglitazone, FDC formulation C8
DRUG: Linagliptin tablet
DRUG: pioglitazone tablet (Actos®)

Sponsor

Boehringer Ingelheim